- Home
- ETR vs INSM Comparison
ETR vs INSM Comparison
Compare ETR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETR
- INSM
- Stock Information
- Founded
- ETR 1949
- INSM 1988
- Country
- ETR United States
- INSM United States
- Employees
- ETR N/A
- INSM N/A
- Industry
- ETR Electric Utilities: Central
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- ETR Utilities
- INSM Health Care
- Exchange
- ETR Nasdaq
- INSM Nasdaq
- Market Cap
- ETR N/A
- INSM 12.6B
- IPO Year
- ETR N/A
- INSM 2000
- Fundamental
- Price
- ETR $83.31
- INSM $65.63
- Analyst Decision
- ETR Buy
- INSM Strong Buy
- Analyst Count
- ETR 14
- INSM 16
- Target Price
- ETR $83.67
- INSM $95.36
- AVG Volume (30 Days)
- ETR 3.3M
- INSM 2.7M
- Earning Date
- ETR 04-29-2025
- INSM 05-08-2025
- Dividend Yield
- ETR 3.56%
- INSM N/A
- EPS Growth
- ETR N/A
- INSM N/A
- EPS
- ETR 3.09
- INSM N/A
- Revenue
- ETR $11,931,899,000.00
- INSM $381,030,000.00
- Revenue This Year
- ETR $10.47
- INSM $30.36
- Revenue Next Year
- ETR $6.41
- INSM $115.55
- P/E Ratio
- ETR $27.00
- INSM N/A
- Revenue Growth
- ETR N/A
- INSM 20.77
- 52 Week Low
- ETR $52.07
- INSM $21.92
- 52 Week High
- ETR $88.38
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- ETR 49.29
- INSM 36.78
- Support Level
- ETR $81.44
- INSM $67.21
- Resistance Level
- ETR $84.96
- INSM $73.39
- Average True Range (ATR)
- ETR 1.87
- INSM 2.69
- MACD
- ETR 0.04
- INSM -0.19
- Stochastic Oscillator
- ETR 66.26
- INSM 19.00
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.